Scholar Rock to Present at Upcoming Healthcare Conferences
03 November 2021 - 7:01AM
Business Wire
Scholar Rock (NASDAQ: SRRK), a clinical-stage biopharmaceutical
company focused on the treatment of serious diseases in which
protein growth factors play a fundamental role, today announced
that management will participate in the following upcoming investor
conferences:
- Credit Suisse 30th Annual Virtual Healthcare Conference on
Tuesday, November 9th, 2021 at 8:50 a.m. ET.
- Cowen 5th Annual IO Next Virtual Summit on Monday, November
15th, 2021 at 8:15 a.m. ET.
- 12th Annual Jefferies Global Healthcare Conference in London on
Wednesday, November 17th, 2021 at 5:00 p.m. GMT (11:00 a.m.
ET).
- 33rd Annual Piper Sandler Virtual Healthcare Conference on
November 30th-December 2nd, 2021. The webcast will be available
beginning at 10:00 a.m. ET on November 22.
A live webcast of presentations at the Credit Suisse, Cowen and
Jefferies conferences may be accessed by visiting the Investors
& Media section of the Scholar Rock website at
http://investors.scholarrock.com. All these webcasts will be
archived and available on the Company’s website for approximately
90 days following the presentation.
About Scholar Rock
Scholar Rock is a clinical-stage biopharmaceutical company
focused on the discovery and development of innovative medicines
for the treatment of serious diseases in which signaling by protein
growth factors plays a fundamental role. Scholar Rock is creating a
pipeline of novel product candidates with the potential to
transform the lives of patients suffering from a wide range of
serious diseases, including neuromuscular disorders, cancer, and
fibrosis. Scholar Rock’s approach to targeting the molecular
mechanisms of growth factor activation enabled it to develop a
proprietary platform for the discovery and development of
monoclonal antibodies that locally and selectively target these
signaling proteins at the cellular level. By developing product
candidates that act in the disease microenvironment, the Company
intends to avoid the historical challenges associated with
inhibiting growth factors for therapeutic effect. Scholar Rock
believes its focus on biologically validated growth factors may
facilitate a more efficient development path. For more information,
please visit www.ScholarRock.com or follow Scholar Rock on Twitter
(@ScholarRock) and LinkedIn
(https://www.linkedin.com/company/scholar-rock/).
Scholar Rock® is a registered trademark of Scholar Rock,
Inc.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20211102005274/en/
Scholar Rock: Investors Stephanie Ascher Stern
Investor Relations, Inc. Stephanie.Ascher@sternir.com
212-362-1200
Media Ariane Lovell Finn Partners
ariane.lovell@finnpartners.com 917-565-2204
Scholar Rock (NASDAQ:SRRK)
Historical Stock Chart
From Jun 2024 to Jul 2024
Scholar Rock (NASDAQ:SRRK)
Historical Stock Chart
From Jul 2023 to Jul 2024